Hino, Masayuki
Matsumura, Itaru
Fujisawa, Shin
Ishizawa, Kenichi
Ono, Takaaki
Sakaida, Emiko
Sekiguchi, Naohiro
Tanetsugu, Yusuke
Fukuhara, Kei
Ohkura, Masayuki
Koide, Yuichiro
Takahashi, Naoto
Article History
Received: 20 December 2019
Revised: 3 April 2020
Accepted: 3 April 2020
First Online: 11 April 2020
Compliance with ethical standards
:
: Masayuki Hino reports research funding from Pfizer, Novartis, and Otsuka, and honoraria from Pfizer, Novartis, Otsuka, and Bristol-Myers Squibb. Itaru Matsumura reports research funding from Pfizer and Otsuka, speakers bureau with Novartis and Bristol-Myers Squibb, and consultancy with Otsuka. Shin Fujisawa reports honoraria and research funding from Novartis, Pfizer, Otsuka, and Bristol-Myers Squibb. Kenichi Ishizawa reports research funding from Pfizer and Otsuka and speakers bureau with Novartis and Bristol-Myers Squibb. Takaaki Ono reports honoraria from Celgene, Merck Sharp & Dohme, Ono, Novartis, Bristol-Myers Squibb, Pfizer, Otsuka, and Takeda and research funding from, Celgene, Merck Sharp & Dohme, Ono, Kyowa Hakko Kirin, and Chugai. Emiko Sakaida reports research funding from Bristol-Myers Squibb, Chugai, Ono, and Kyowa Kirin. Naohiro Sekiguchi reports research funding from Ono, A2 Healthcare, Astellas, Janssen, Merck Sharp & Dohme, Otsuka, Pfizer, PPD-SNBL, Sumitomo Dainippon Pharma, Daiichi Sankyo Company, and Bristol-Myers Squibb. Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, and Yuichiro Koide report employment by Pfizer R&D Japan G.K. Naoto Takahashi reports research funding and honoraria from Pfizer, Otsuka, and Novartis, and research funding from Chugai, Eizai, Asahikasei, Ono, Kyowahakko-Kirin, and Toyamakagaku, outside the submitted work.